ABBV vs. SPCX: AbbVie vs. Space Exploration Stock Comparison

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Space Exploration (SPCX) belongs to Communication Services (Telecommunication Services) — their GICS classifications point to very different parts of the market.

AbbVie (ABBV) has been public since January 2, 2013 with a meaningfully longer listed history, while Space Exploration (SPCX) only listed on June 12, 2026 — long-window metrics on the SPCX side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Space Exploration (SPCX) has a highly aggressive beta of 5.69, indicating much higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.21 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both ABBV and SPCX need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Neither AbbVie (ABBV) nor Space Exploration (SPCX) reports a ROE value for this period, so a direct comparison isn’t possible.

Space Exploration (SPCX) reports a negative net margin of -8.61%, usually indicating a net loss over the period. Meanwhile AbbVie (ABBV) reports 15.67%, ranking against industry peers normally.

Both AbbVie (ABBV) at 39.59% and Space Exploration (SPCX) at 27.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Space Exploration (SPCX) at 33.24% clears its industry range for revenue growth, far stronger top-line momentum than AbbVie (ABBV) at 8.57%, which is closer to a typical peer reading.

AbbVie (ABBV) at -0.84% is around its peer norm for EPS growth, while Space Exploration (SPCX) at -25,600.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Space Exploration (SPCX) at 3.08 carries current ratio above its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Only one side’s leverage can be read here: Space Exploration (SPCX) carries debt-to-equity ratio of 0.22 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Space Exploration (SPCX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Space Exploration (SPCX) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: AbbVie (ABBV) at 50.05 sits in the richer P/E ratio quartile, and Space Exploration (SPCX) at 583.78 is richer still, above its industry range.

AbbVie (ABBV) at 7.80 prices around its industry’s typical P/S ratio, while Space Exploration (SPCX) at 56.91 clears its benchmark range — SPCX looks notably rich on sales.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Space Exploration (SPCX) reports 10.31, ranking against industry peers normally.

Valuation Metrics